Please assess the completion status of the following clinical trial:

Trial Title: Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulant subjects with Duchenne muscular dystrophy resulting from a mutation in the DMD gene, confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation) or H-RMCA (High-Resolution Melting Curve Analysis), and correctable by GSK2402968-induced DMD exon 51 skipping,~* Males, at least 5 years of age and with a life expectancy of at least 1 year~* Able to rise from floor in ≤7 seconds (without aids/orthoses),~* Able to complete the 6MWD test with a distance of at least 75m~* Receiving glucocorticoids for a minimum of 6 months immediately prior to screening, with no significant change in total daily dosage or dosing regimen for a minimum of 3 months immediately prior to screening and a reasonable expectation that total daily dosage and dosing regimen will not change significantly for the duration of the study~* QTc \<450msec~* On adequate contraception~* Able to comply with and complete all protocol requirements~Exclusion Criteria:~* any additional missing exon for DMD~* Current of history of liver or renal disease or impairment~* Acute illness within 4 weeks of the first dose~* Use of prohibited meds within 6 months of fist dose~* Current participation in any other investigational clinical trial~* Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test at screening~* Symptomatic cardiomyopathy~* Children in Care

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous regimen; 6mg/kg once weekly (Type: EXPERIMENTAL): Once Weekly
- Intermittent regimen; 6mg/kg twice weekly (Type: EXPERIMENTAL): Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).